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Introduction 
 
Haematopoietic stem cell transplantation (HSCT) is used to treat malignant and non-
malignant diseases. Apart from clinical and Human Leukocyte Antigen (HLA)-related 
factors, non-HLA Immunogenetics is being increasingly recognized to play a role in 
the outcome of HSCT. A gene that may be relevant for the outcome of HSCT is 
TGFB1, which encodes Transforming Growth Factor β 1 (TGF-β1), a cytokine that is 
central in the regulation of numerous immune processes. Several polymorphisms in 
TGFB1 have been identified and some of them are known to cause alterations in 
cytokine secretion. We and others have previously shown that polymorphisms within 
TGFB1 affect the outcome of HSCT. Regulatory T cells (Treg) are major producers of 
TGF-β1 and play a fundamental role in immune events in HSCT. Consequently, the 
aim of this project is to study the effect of TGFB1 polymorphisms on the function of 
Treg and their role in HSCT complications such as graft-versus-host disease.  
 
Materials and Methods 
 
Peripheral blood from healthy volunteer donors was obtained by venipuncture. DNA 
was extracted by an in-house salting-out method. Molecular typing techniques were 
used to type TGFB1 +29 T>C polymorphism. Volunteer donors were grouped in three 
genotype categories for further experiments. Peripheral blood mononuclear cells 
(PBMC) were isolated by ficoll gradient, and Treg (CD4+CD25++CD127loFOXP3+) and 
effector (CD4+CD25-CD127hiFOXP3-) cells were isolated with a microbead-based 
method (Figure 1). 
 
Isolated Treg and effector cells were stimulated with antiCD3/CD28 antibodies and 
cultured in vitro in 96-round bottom well plates. Latency-associated-peptide (LAP, 
membrane-bound TGF-β1) expression was measured on resting and stimulated cells 
by flow-cytometric analysis at specific time-points. 
 
Conclusions 
 
TGFB1 +29 T>C genotype seems to influence the amount of membrane-bound TGF-
β1 expressed exclusively by in vitro TCR-stimulated Treg. The presence of a C allele 
confers a trend towards higher production of LAP by these cells in a dominant model. 
Differences in the levels of LAP on Treg may affect the function of these cells in an 
inflammatory context such as that present in HSCT patients. Consequently, this 
possibility must be explored and further experiments are being developed in order to 
address these questions.   
 
Future work 
 
We are currently undertaking RT-Q-PCR experiments in order to characterise the 
effect of TGFB1 +29 T>C polymorphism on the expression of this cytokine by Treg 
and effector CD4+ cells at the RNA level. Additionally, we are developing optimised 
autologous suppression assays in order to evaluate the functional effect of TGFB1 
polymorphisms on immune modulation by Treg. 
 
In the future, we will extend our analysis to other polymorphisms within the regulatory 
region of TGFB1, and perform haplotype analysis on the joint effect of these 
polymorphisms on the outcome of HSCT and on the function of Treg. 
 
These data will hopefully help to identify the risk factors associated with TGFB1 
expression in patients and donors and to generate clinically useful algorithms of 
genetic risk assessment in HSCT.   
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Results 
 
Molecular typing techniques for the detection of TGFB1 +29T>C SNP have been 
employed to type 31 healthy blood donors recruited for functional experiments. 
Figure 2 shows representative results for the 3 TGFB1 +29 T>C genotypes as 
identified by sequencing.  
 
Membrane-bound TGF-β1 (LAP positivity) upon TCR stimulation of isolated Treg has 
been confirmed to be specific to this cell subset (Figure 3). LAP levels have been 
assessed in 5 donors per TGFB1 +29T>C genotype. The in vitro kinetics of TGF-β1 
induction on these cells after TCR stimulation with soluble antibodies against CD3 
and CD28 was shown to peak at 24h of incubation and to reach an average of 25.7% 
of the CD4+CD25++CD127lo cells (range 11.0-51.2%), followed by a reduction to low 
levels by 48h, which remain constant up to 96h (Figure 4). TCR stimulation with 
plate-bound antibodies produces maximal and sustained LAP expression on Treg 
(Figure 5). A trend towards a higher percentage of LAP+ Treg generated after soluble 
activation when the cells bear a +29C allele (Pro10 on its signal peptide) was 
identified (p=0.066) (Figure 6).  
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Figure 3 LAP expression on activated Treg (and not on effector 
CD4 cells) peaks at 24h of incubation. Isolated Treg and effector CD4 
cells were activated with soluble anti-CD3 and anti-CD28 in the 
presence of IL-2. LAP positivity was determined at t=0, 24 and 48h of 
incubation by flow cytometry. (A) LAP (y axis) vs. CD4 (top row) and 
CD127 (bottom row) staining on isolated Treg after 0, 24 and 48h of 
incubation. Plots generated by gating on live cells (top row) and on 
CD4+ cells (bottom row). (B) Histogram for LAP staining on Treg at 
different time points after activation. Cells gated on lymphocytes. (C) 
Histogram for LAP staining on effector CD4 cells at different time points 
after activation. Cells gated on lymphocytes. 
	

Figure 4 LAP+ cells after TCR stimulation in isolated 
Treg (CD4+CD25+CD127lo) and Effector (CD4+CD25-
CD127hi) lymphocytes. In a series of independent 
experiments, isolated Treg (red) and effector (blue) cells 
were activated with soluble anti-CD3 and anti-CD28 in the 
presence of IL-2 and cultured for different periods. The 
cells were harvested at specific time points and surface 
LAP expression was assessed by flow cytometry. 
	

Figure 6 LAP expression on Treg upon TCR 
stimulation differs according to TGFB1 codon 10 
+29T>C genotype. A total of 15 independent Treg 
activation experiments (5 per genotype) were performed 
and LAP expression was assessed at 24h of incubation 
with soluble anti-CD3 and anti-CD28. (A) Percentage of 
LAP+ cells within the CD4+CD25+CD127lo gate according 
to their TGFB1 +29 T>C genotype. (B) The same results 
grouped according to the presence or absence of a C 
allele on TGFB1 +29 T>C. (C) Median fluorescence 
intensity (MFI) of the LAP+ cells according to their TGFB1 
+29 T>C genotype. (D) The same results grouped 
according to the presence or absence of a C allele at 
TGFB1 +29 T>C.   
	

Figure 1 Example of a regulatory T cell isolation 
procedure. PBMC (top row) obtained from healthy 
volunteer donors were used to isolate CD4+CD25- (third 
row) and CD4+CD25+ (bottom row) cells. The second row 
shows the CD4-depleted fraction. The first column shows 
the forward and side scatter plots (y axis) and lymphocyte 
gate. The second and third columns show scatter plots for 
CD4 (y axis) vs. CD25 expression and forward scatter on 
the lymphocytes, respectively. The fourth column shows 
CD127 (y axis) vs. CD25 expression scatter plots gated on 
the CD4+ lymphocytes. Plots generated with Flojo software 
(v. 6.4.7, Tree Star Inc., Ashland, USA). 
	

Figure 2 Three TGFB1 signal peptide region 
sequencing results showing +29T>C. (A) CC 
individual. (B) TC individual. (C) TT individual. 
Sequences analysed with Sequencing Analysis 5.2 (PE 
Applied Biosystems, Foster City, CA, USA). 
	

Figure 5 LAP expression on Treg is maximal and sustained after 
plate-bound TCR stimulation. Isolated Treg (red) and effector CD4 
(blue) cells were stimulated with plate-bound anti-CD3 and anti-CD28 in 
the presence of IL-2. LAP staining (y axis) was assessed at different 
time points after incubation. Gated on live cells.  
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